CBD for illnesses
by 5 LEAF PRODUCTS © 2024
Krebs - Heider et al. (2022)
The effects of CBD on relieving cancer symptoms are currently being researched.
Initial studies indicate that CBD may have positive effects on pain associated with the disease and side effects of chemotherapy.
The potential effects of CBD in cancer patients likely depend on various factors (e.g., quality, composition, and method of application) and have not yet been sufficiently investigated. Mechanisms of action, boundary conditions, and side effects in this regard remain unclear.
Possible mechanisms include the activation of CB1, CB2 and TRPV1 receptors, the induction of apoptosis in cancer cells, the suppression of invasiveness, as well as tumor migration and metastasis, and the enhancement of the efficacy of chemotherapeutic agents.
Heider, CG, Itenberg, SA, Rao, J., Ma, H., & Wu, X. (2022). Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review. Biology, 11(6), 817. https://doi.org/10.3390/biology11060817
Lung cancer - Issaris et al. (2022)
CBD may have an antineoplastic effect on lung cancer cells. Through various mechanisms, some of which may be mediated via cannabinoid receptors, CBD has successfully limited the spread of malignant tumors in animal studies.
Several studies have shown that CBD induces apoptosis in malignant tumor cells, leading to their death. Furthermore, CBD has been shown to reduce the potential for cancer cell migration. In several animal studies, CBD has demonstrated potential antitumorigenic activity.
However, the current state of research in this area is insufficient to draw precise conclusions about humans.
Issaris, V., Milas, GP, & Zareifopoulos, N. (2022). Antitumorigenic Effect of Cannabidiol in Lung Cancer: What Do We Know So Far? – a mini review. Iranian Biomedical Journal, 26(6), 406-413. https://doi.org/10.52547/ibj.3732
MS (Multiple Sclerosis) - Furgiuele et al. (2021)
There are indications that CBD may have immunomodulatory properties.
CBD is therefore often mentioned as a possible therapy for the most common chronic autoimmune disease of the central nervous system, multiple sclerosis (MS).
In animal studies (mainly on mice), CBD proved to be a promising agent for combating similar autoimmune diseases.
Clinical studies on this topic are scarce and have not yet been able to confirm this assumption. It is possible that the CBD doses or the duration of administration in the relevant studies were too low.
The aim is to identify possible mechanisms by which CBD could support MS therapy.
Furgiuele, A., Cosentino, M., Ferrari, M., & Marino, F. (2021). Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: A Systematic Review. Journal of Neuroimmune Pharmacology, 16(2), 251-269. https://doi.org/10.1007/s11481-021-09982-7
Parkinson's Syndrome - White (2019)
In a study investigating the effectiveness of CBD in Parkinson's disease, patients were given either a placebo, 75mg of CBD, or 300mg of CBD daily for six weeks.
Those who took 300mg of CBD daily reported significant improvements in their quality of life compared to the placebo group. There was also evidence of improved sleep with CBD use.
This study does not rule out the specific effect of CBD on symptoms of Parkinson's syndrome, but it appears to be limited.
Further research on CBD in this context is needed.
White, CM (2019). A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. The Journal of Clinical Pharmacology, 59(7), 923-934. https://doi.org/10.1002/jcph.1387
Epilepsy - White (2019)
CBD is able to significantly reduce the number of epileptic seizures in children and adults.
In a study, the frequency of convulsive seizures decreased significantly with daily oral administration of 20mg CBD per kg body weight in addition to existing medication over several weeks.
After 14 weeks, 5% of participants were seizure-free, and in 43%, seizure frequency was reduced by at least 50%. Patient condition improved in 62% of the individuals in the CBD group.
In the aforementioned aspects, CBD was clearly superior to a placebo. Several other studies showed similarly positive effects of supplemental CBD use in various forms of epilepsy.
White, CM (2019). A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. The Journal of Clinical Pharmacology, 59(7), 923-934. https://doi.org/10.1002/jcph.1387
Epilepsy - Lattanzi et al. (2018)
There is strong evidence that CBD can have an anti-seizure effect in various forms of epilepsy.
Thus, CBD use as a complementary therapy can help reduce seizure frequency in both people with Lennox-Gastaut syndrome and people with Dravet syndrome.
The frequency of seizures was reduced by an average of 19.5% more in people who were given a total of 10 mg of CBD per kg of body weight daily for several weeks than in people in the placebo group.
With a daily dose of 20 mg CBD per kg, seizure frequency was reduced by an average of 19.9% more compared to the placebo group. A reduction in seizure frequency of at least 50% was observed in 37.2% of cases with daily 20 mg CBD, compared to only 21.2% of cases with placebo.
Seizures in particular seem to decrease with CBD, but there was also a descriptive trend of decrease in non-convulsive seizures associated with CBD administration.
Common adverse effects of CBD in this study included decreased appetite and increased drowsiness; elevated serum aminotransferases were also observed.
In each case, CBD was administered orally, divided into two equal doses per day, and in combination with antiepileptic drugs.
Approximately 65 million people worldwide suffer from epilepsy. A large proportion of those affected cannot benefit from appropriate therapy.
New treatment options are therefore being intensively researched. CBD could contribute to better outcomes.
Lattanzi, S., Brigo, F., Trinka, E., Zaccara, G., Cagnetti, C., Del Giovane, C., & Silvestrini, M. (2018). Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs, 78(17), 1791-1804. https://doi.org/10.1007/s40265-018-0992-5
MS (Multiple Sclerosis) - Rudroff and Sosnoff (2018)
The authors investigated whether CBD could be a suitable means of increasing the physical mobility of people with multiple sclerosis (MS).
They discussed CBD as a mediating process that could reduce MS symptoms such as fatigue, pain, inflammation, spasticity and depression.
There is evidence that CBD could inhibit inflammatory processes, such as those involved in the debilitating condition of fatigue. These and other connections could improve the mobility of MS patients.
To verify these hypothesized therapeutic mechanisms and outcomes of CBD, clinical studies are needed, which have not yet been conducted.
CBD is generally considered a well-tolerated and relatively safe substance. However, it could interact with medications. This needs to be investigated.
Rudroff, T., & Sosnoff, J. (2018). Cannabidiol to Improve Mobility in People with Multiple Sclerosis. Frontiers in Neurology, 9. https://doi.org/10.3389/fneur.2018.00183
Alzheimer's - Watt & Karl (2017)
Alzheimer's disease is a neurodegenerative disease. Currently, there is no therapy that can halt or even reverse its progression.
CBD is currently being discussed as a potential therapeutic option for Alzheimer's patients in several ways.
In animal studies, administering CBD was able to prevent and even reverse cognitive deficits caused by Alzheimer's disease.
At the cellular level, CBD was able to partially counteract the progression of the disease.
Future studies should consider CBD as a possible alternative or supplement for Alzheimer's therapy and examine the mechanisms in more detail.
No effect has yet been proven in humans.
Watt, G., & Karl, T. (2017). In Vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Frontiers in Pharmacology, 8. https://doi.org/10.3389/fphar.2017.00020
Would you like to learn about the current state of research regarding the use and effects of CBD on a specific disease?
Then please use our contact form , and our team of experts will take care of researching and preparing the information.